{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    42,
    43,
    44,
    45,
    47,
    48,
    49,
    50,
    60,
    63,
    73,
    74,
    75,
    76,
    77,
    78,
    111
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_4",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "first dose"
      },
      {
        "id": "anchor_1",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Randomization visit"
      },
      {
        "id": "anchor_2",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "screening period"
      },
      {
        "id": "anchor_3",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed \nconsent"
      },
      {
        "id": "anchor_5",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_7",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "Once daily"
      },
      {
        "id": "rep_daily_9",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_13",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P28D",
        "endOffset": "-P1D",
        "sourceText": "Day-28 to Day-1"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "-P28D",
        "endOffset": "-P1D",
        "sourceText": "Day -28 to Day -1"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "sourceText": "Screening \nPeriod"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "Screening period"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "Screening Period"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "Washout period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "observation \nperiod"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "7 days pre"
      },
      {
        "id": "rep_window_20",
        "type": "Continuous",
        "sourceText": "24 hours before"
      },
      {
        "id": "rep_window_21",
        "type": "Continuous",
        "sourceText": "8 days before"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "P0D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "End of study period",
        "sourceText": "To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio)"
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "P0D",
        "minObservations": 1,
        "exitCondition": "End of study period",
        "sourceText": "ARR during the study period assessed by confirmed protocol-defined adjudicated relapses"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_2",
          "epoch_3",
          "epoch_5",
          "epoch_6"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "End of Study Visit",
          "End of Study",
          "Day 1",
          "Screening",
          "Safety Follow-up Visit"
        ],
        "sourceText": "[{'condition': 'If subject experiences AE requiring discontinuation', 'path': ['DEFINITIVE_DISCONTINUATION', 'EARLY_TERMINATION_VISIT', 'SAFETY_FOLLOW_UP']}, {'condition': 'Temporary discontinuation for safety', 'path': ['TEMPORARY_DISCONTINUATION', 'RECHALLENGE', 'RESUME_TREATMENT']}, {'condition': 'Suspected MS Relapse', 'path': ['UNSCHEDULED_ASSESSMENT_VISIT']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 1"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ae",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Concomitant \nMedications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 3"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Recurring",
        "rationale": "RECURRING signals: 1"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Liver function test monitoring",
        "executionType": "Episode",
        "rationale": "Appendix 6 describes actions and follow-up assessments based on specific liver safety results, indicating a conditional workflow."
      },
      {
        "activityId": "Schedule of Activities (SoA) Assessments",
        "executionType": "Recurring",
        "rationale": "The protocol mentions a Schedule of Activities with visits including Week 3, indicating assessments are repeated at scheduled study visits."
      },
      {
        "activityId": "CYP3A and CYP2C8 inhibitor restriction",
        "executionType": "Window",
        "rationale": "The prohibited use of specific drugs and grapefruit juice represents a continuous restriction period during the trial."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "general",
        "text": "a. Screening period can range from D-28 to D-1",
        "footnoteId": "fn_1",
        "structuredCondition": "visit.window(D-28, D-1)",
        "appliesToActivityIds": [
          "Screening"
        ],
        "sourceText": "a. Screening period can range from D-28 to D-1"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "general",
        "text": "b. From D1 to EOS, unscheduled visits may be performed at any time by the Investigator",
        "footnoteId": "fn_2",
        "structuredCondition": "visit.unscheduled(D1, EOS)",
        "appliesToActivityIds": [
          "Unscheduled Visits"
        ],
        "sourceText": "b. From D1 to EOS, unscheduled visits may be performed at any time by the Investigator"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c. At the EOS, the participants who have completed the study and remain on IMP will be offered participation in a long-term safety study.",
        "footnoteId": "fn_3",
        "structuredCondition": "participant.status == 'completed' && participant.on_imp == true",
        "appliesToActivityIds": [
          "Long-term safety study enrollment"
        ],
        "sourceText": "c. At the EOS, the participants who have completed the study and remain on IMP will be offered parti"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d. These visits may be done as home health visits (where applicable) or onsite visits",
        "footnoteId": "fn_4",
        "structuredCondition": "visit.location IN ['home', 'onsite']",
        "appliesToActivityIds": [
          "All visits"
        ],
        "sourceText": "d. These visits may be done as home health visits (where applicable) or onsite visits"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "e. If a participant prematurely discontinues treatment with IMP, the participant will undergo a premature EOT visit as soon as possible.",
        "footnoteId": "fn_5",
        "structuredCondition": "if(imp.discontinuation == true) then(visit.trigger(EOT))",
        "appliesToActivityIds": [
          "EOT visit"
        ],
        "sourceText": "e. If a participant prematurely discontinues treatment with IMP, the participant will undergo a prem"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "f. Common EOS visit will be done when the prespecified number of events for 6-month CDW is expected to be reached.",
        "footnoteId": "fn_6",
        "structuredCondition": "visit.trigger(event_count >= target_6m_cdw)",
        "appliesToActivityIds": [
          "Common EOS visit"
        ],
        "sourceText": "f. Common EOS visit will be done when the prespecified number of events for 6-month CDW is expected "
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "t. Pharmacodynamics/biomarkers samples collected are not timed samples.",
        "footnoteId": "fn_8",
        "structuredCondition": "sample.timing == 'untimed'",
        "appliesToActivityIds": [
          "Pharmacodynamics samples",
          "Biomarkers samples"
        ],
        "sourceText": "t. Pharmacodynamics/biomarkers samples collected are not timed samples."
      },
      {
        "id": "fn_cond_8",
        "conditionType": "timing_after",
        "text": "u. The DNA testing may be done, if locally applicable, at any time after signature of consent.",
        "footnoteId": "fn_9",
        "structuredCondition": "if(local_regulations.allow == true) then(activity.start >= consent.date)",
        "appliesToActivityIds": [
          "DNA testing"
        ],
        "sourceText": "u. The DNA testing may be done, if locally applicable, at any time after signature of consent."
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "v. This sample will be collected and stored for use if any unexpected safety issue occurs.",
        "footnoteId": "fn_10",
        "structuredCondition": "if(safety_issue == 'unexpected') then(sample.analyze())",
        "appliesToActivityIds": [
          "Safety sample collection",
          "Sample storage"
        ],
        "sourceText": "v. This sample will be collected and stored for use if any unexpected safety issue occurs."
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Adjudicated Relapse Rate",
        "endpointType": "Primary",
        "inputs": [
          "Relapse events",
          "Adjudication status",
          "Time on study"
        ],
        "timeWindow": {
          "reference": "Randomization",
          "duration": "Study duration"
        },
        "algorithm": "Total number of adjudicated relapses / Total person-years of exposure",
        "successCriteria": "Statistically significant reduction compared to control (alpha = 0.05)",
        "sourceText": "Adjudicated relapse rate is the primary endpoint in this trial, being a standard endpoint used in pivotal RMS clinical studies"
      },
      {
        "id": "ep_2",
        "name": "Secondary: 6-month Confirmed Disability Worsening (CDW)",
        "endpointType": "Secondary",
        "inputs": [
          "EDSS score",
          "Relapse onset date",
          "Relapse resolution date",
          "Screening EDSS"
        ],
        "timeWindow": {
          "reference": "Initial onset of disability worsening",
          "duration": "P6M"
        },
        "algorithm": "Increase in EDSS score maintained for >= 6 months. Confirmation EDSS must be > 30 days after onset of confirmed relapse and in absence of ongoing relapse. Minimum increase must be maintained for any intervening assessments.",
        "successCriteria": "Maintenance of minimum EDSS increase for 6 months; imputed via logistic model if study ends prior to confirmation.",
        "sourceText": "Six-month confirmed disability worsening (CDW) is selected as the key secondary endpoint... for the purpose of confirmation, only EDSS score(s) measured more than 30 days after the onset of a confirme"
      },
      {
        "id": "ep_3",
        "name": "Safety: Treatment-Emergent Adverse Events (TEAE)",
        "endpointType": "Secondary",
        "inputs": [
          "Adverse Event (AE) onset date",
          "Study intervention start date",
          "AE severity/seriousness"
        ],
        "timeWindow": {
          "reference": "Treatment period",
          "duration": "Duration of exposure"
        },
        "algorithm": "Count of AEs that developed, worsened, or became serious during the treatment period",
        "successCriteria": "Descriptive analysis (no formal success/failure statistical criteria)",
        "sourceText": "TEAEs are defined as AEs that developed, or worsened, or became serious during the treatment period."
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Annualized Adjudicated Relapse Rate (ARR)",
        "variableType": "Custom",
        "sourceVariables": [
          "Adjudicated relapses",
          "Randomization date",
          "EOS date",
          "Last contact date"
        ],
        "derivationRule": "Total number of adjudicated relapses divided by observation duration (randomization to EOS or last contact), analyzed via negative binomial regression with log-transformed duration as offset.",
        "baselineDefinition": "Not applicable (rate over study period)",
        "baselineVisit": "N/A",
        "analysisWindow": "Randomization to End of Study (EOS) or last contact",
        "imputationRule": "No imputation for unobserved events after study discontinuation",
        "unit": "Relapses per year"
      },
      {
        "id": "dv_2",
        "name": "Time to onset of 6-month Confirmed Disability Worsening (CDW)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "EDSS score",
          "Baseline EDSS"
        ],
        "derivationRule": "Time from randomization to first EDSS increase (>=1.5 if baseline 0; >=1.0 if baseline 0.5-5.5; >=0.5 if baseline >5.5) confirmed at a visit >= 6 months later.",
        "baselineDefinition": "Baseline Expanded Disability Status Scale (EDSS) score",
        "baselineVisit": "Baseline",
        "analysisWindow": "Randomization to EOS",
        "imputationRule": "Kaplan-Meier estimates for censored data",
        "unit": "Days/Months"
      },
      {
        "id": "dv_3",
        "name": "Total number of new and/or enlarging T2-hyperintense lesions",
        "variableType": "Composite",
        "sourceVariables": [
          "T2-hyperintense lesions"
        ],
        "derivationRule": "Sum of the individual number of new and/or enlarging T2 lesions at all scheduled visits starting after baseline up to and including the EOS visit.",
        "baselineDefinition": "MRI findings at baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "Post-baseline visits through EOS",
        "imputationRule": "Not specified",
        "unit": "Count"
      },
      {
        "id": "dv_4",
        "name": "Total number of new Gd-enhancing T1-hyperintense lesions",
        "variableType": "Composite",
        "sourceVariables": [
          "Gd-enhancing T1-hyperintense lesions"
        ],
        "derivationRule": "Sum of the individual number of new Gd-enhancing T1-hyperintense lesions at all scheduled visits starting after baseline up to and including the EOS visit.",
        "baselineDefinition": "MRI findings at baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "Post-baseline visits through EOS",
        "imputationRule": "Not specified",
        "unit": "Count"
      },
      {
        "id": "dv_5",
        "name": "Time to Confirmed Disability Improvement (CDI)",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "EDSS score",
          "Baseline EDSS"
        ],
        "derivationRule": "Time to a >=1.0 point decrease on the EDSS from baseline confirmed over at least 6 months.",
        "baselineDefinition": "Baseline Expanded Disability Status Scale (EDSS) score",
        "baselineVisit": "Baseline",
        "analysisWindow": "Randomization to EOS",
        "imputationRule": "Not specified",
        "unit": "Days/Months"
      },
      {
        "id": "dv_6",
        "name": "Percent change in brain volume loss",
        "variableType": "PercentChange",
        "sourceVariables": [
          "Brain volume"
        ],
        "derivationRule": "((EOS_value - Month6_value) / Month6_value) * 100",
        "baselineDefinition": "Month 6 brain MRI scan",
        "baselineVisit": "Month 6",
        "analysisWindow": "Month 6 to EOS",
        "imputationRule": "Not specified",
        "unit": "%"
      },
      {
        "id": "dv_7",
        "name": "Change in cognitive function (SDMT)",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Symbol Digit Modalities Test (SDMT) score"
        ],
        "derivationRule": "EOS_score - baseline_score",
        "baselineDefinition": "Baseline SDMT score",
        "baselineVisit": "Baseline",
        "analysisWindow": "Baseline to EOS",
        "imputationRule": "Not specified",
        "unit": "Score"
      },
      {
        "id": "dv_8",
        "name": "Change in MSQoL-54 questionnaire score",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "MSQoL-54 score"
        ],
        "derivationRule": "EOS_score - baseline_score",
        "baselineDefinition": "Baseline MSQoL-54 score",
        "baselineVisit": "Baseline",
        "analysisWindow": "Baseline to EOS",
        "imputationRule": "Not specified",
        "unit": "Score"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Year 1 (M12)",
        "From M15 to EOS",
        "End of Study",
        "Follow-up",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Year 1 (M12)",
          "trigger": "Progress to Year 1 (M12)"
        },
        {
          "fromState": "Year 1 (M12)",
          "toState": "From M15 to EOS",
          "trigger": "Progress to From M15 to EOS"
        },
        {
          "fromState": "From M15 to EOS",
          "toState": "End of Study",
          "trigger": "Progress to End of Study"
        },
        {
          "fromState": "End of Study",
          "toState": "Follow-up",
          "trigger": "Progress to Follow-up"
        }
      ],
      "epochIds": {
        "Screening": "epoch_1",
        "Year 1 (M12)": "epoch_2",
        "From M15 to EOS": "epoch_3",
        "End of Study": "epoch_5",
        "Follow-up": "epoch_6",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "SAR442168",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 60.0,
            "unit": "mg"
          },
          {
            "amount": 14.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "36 months",
        "sourceText": "ation on Day 1. Screening Period Treatment Period : approximately 18 to 36 months All patients continue in the study until Common Study End (EOS) 0 12 24 15 18 Months Teriflunomide 14 mg Oral N=450 SA"
      },
      {
        "id": "dosing_2",
        "treatmentName": "the SAR442168",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 30.0,
            "unit": "mg"
          },
          {
            "amount": 60.0,
            "unit": "mg"
          }
        ],
        "sourceText": "ug by the Investigators. Both participants completed the DRI15928 study and successfully rolled over to the LTS follow-up study. • One event of mild petechia in a female participant (at Week 8 in the "
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "SAR442168 (Tolebrutinib)",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "",
            "description": "Dose not specified in provided text snippet"
          }
        ],
        "durationDescription": "Not specified in text",
        "doseModifications": [
          "Liver function test monitoring guidance included for dose management"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Teriflunomide (Aubagio)",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 0.0,
            "unit": "mg",
            "description": "Standard clinical dose"
          }
        ],
        "durationDescription": "Not specified in text"
      },
      {
        "id": "dosing_llm_3",
        "treatmentName": "Placebo",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "durationDescription": "Not specified in text"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_8",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "(EDSS) score at screening (<4 versus ≥4) and geographic region (US versus non-US). Study intervention(s) Investigational medicinal product"
      },
      {
        "id": "visit_2",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "10.6 Appendix 6: Liver and other safety: actions and follow-up assessments Liver function test monitoring guidance"
      },
      {
        "id": "visit_4",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Treatment",
        "sourceText": "- increase of ≥1.5 points from the baseline Expanded Disability Status Scale (EDSS) score when the baseline score is 0, OR"
      },
      {
        "id": "visit_5",
        "visitName": "EOS",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Treatment",
        "sourceText": "Study (EOS) visit and number of new and/or enlarging T2-hyperintense lesions by visit over time •"
      },
      {
        "id": "visit_6",
        "visitName": "Month 6",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "epoch": "Treatment",
        "sourceText": "scans at the EOS compared to Month 6 • Change in cognitive function at the EOS compared to baseline"
      },
      {
        "id": "visit_9",
        "visitName": "Month 24",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "The proportion of participants with events at given time points (eg, Month 24) will be calculated using the Kaplan-Meier estimates. In this primary ITT analysis:"
      },
      {
        "id": "visit_12",
        "visitName": "EOT",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "pEOTe EOSf “Common"
      },
      {
        "id": "visit_13",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "sourceText": "Visit number V1 V2"
      },
      {
        "id": "visit_14",
        "visitName": "Visit 2",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "V2 V3"
      },
      {
        "id": "visit_15",
        "visitName": "Visit 3",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "V3 V4"
      },
      {
        "id": "visit_16",
        "visitName": "Visit 4",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "sourceText": "V4 V5"
      },
      {
        "id": "visit_17",
        "visitName": "Visit 5",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "V5 V6, V7"
      },
      {
        "id": "visit_18",
        "visitName": "Visit 6",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "sourceText": "V6, V7 V8"
      },
      {
        "id": "visit_19",
        "visitName": "Visit 7",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "V7 V8"
      },
      {
        "id": "visit_20",
        "visitName": "Visit 8",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 15,
        "sourceText": "V8 V9"
      },
      {
        "id": "visit_21",
        "visitName": "Visit 9",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "sourceText": "V9 V10"
      },
      {
        "id": "visit_22",
        "visitName": "Visit 10",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 17,
        "sourceText": "V10 V11, V12, V13, V14,"
      },
      {
        "id": "visit_23",
        "visitName": "Visit 11",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 18,
        "sourceText": "V11, V12, V13, V14, V15, V16,"
      },
      {
        "id": "visit_24",
        "visitName": "Visit 13",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "sourceText": "V13, V14, V15, V16, V17, V18…"
      },
      {
        "id": "visit_25",
        "visitName": "Visit 15",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 20,
        "sourceText": "V15, V16, V17, V18… V12,"
      },
      {
        "id": "visit_26",
        "visitName": "Visit 17",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 21,
        "sourceText": "V17, V18… V12, V14,"
      },
      {
        "id": "visit_27",
        "visitName": "Visit 12",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 22,
        "sourceText": "V12, V14, V16,"
      },
      {
        "id": "visit_28",
        "visitName": "Visit 14",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 23,
        "sourceText": "V14, V16, V18…"
      },
      {
        "id": "visit_29",
        "visitName": "Visit 16",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 24,
        "sourceText": "V16, V18… pEOTe"
      },
      {
        "id": "visit_30",
        "visitName": "Visit 18",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 25,
        "sourceText": "V18… pEOTe EOS"
      },
      {
        "id": "visit_7",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 26,
        "sourceText": "SAR442168 tablet daily. Randomization will be stratified by the Expanded Disability Status Scale (EDSS) score at screening (<4 versus ≥4) and geographic region (US versus non-US). Study intervention(s"
      },
      {
        "id": "visit_1",
        "visitName": "Week 3",
        "targetDay": 15,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 27,
        "targetWeek": 3,
        "epoch": "Treatment",
        "sourceText": "Week 3 added in the visit header and in footnote ‘l’. Update."
      },
      {
        "id": "visit_32",
        "visitName": "Week 4",
        "targetDay": 22,
        "windowBefore": 4,
        "windowAfter": 4,
        "isRequired": true,
        "visitNumber": 28,
        "targetWeek": 4,
        "sourceText": "within 4 days and 1 during the 60 mg SAR442168 treatment period [at Week 4, 107 U/L (normal range 6 to 34 U/L)]. The participant in the 60 mg group had slightly elevated ALT at screening (48 U/L) and "
      },
      {
        "id": "visit_31",
        "visitName": "Week 8",
        "targetDay": 50,
        "windowBefore": 4,
        "windowAfter": 4,
        "isRequired": true,
        "visitNumber": 29,
        "targetWeek": 8,
        "sourceText": "period [at Week 8, 105 U/L (normal range 6 to 34 U/L)] that returned to normal range within 4 days and 1 during the 60 mg SAR442168 treatment period [at Week 4, 107 U/L (normal range 6 to 34 U/L)]. Th"
      },
      {
        "id": "visit_33",
        "visitName": "Week 16",
        "targetDay": 106,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 30,
        "targetWeek": 16,
        "sourceText": "Week 16 in the SAR442168 30 mg group and 1 event on Day 1 in the SAR442168 60 mg group, with occult blood noted in urine) were reported during the treatment period in the SAR442168 Phase 2b trial. The"
      },
      {
        "id": "visit_3",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 31,
        "sourceText": "and follow-up assessments Liver function test monitoring guidance provided."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Region",
          "categories": [
            "North America",
            "Europe",
            "Asia",
            "Rest of World"
          ],
          "isBlocking": false,
          "sourceText": "the expanded disability status scale \n(edss) score at screening (<4 versus ≥4) and geographic region (us versus non-us)"
        },
        {
          "id": "strat_llm_1",
          "name": "Expanded Disability Status Scale (EDSS) score at screening",
          "categories": [
            "<4",
            "≥4"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_2",
          "name": "Geographic region",
          "categories": [
            "US",
            "non-US"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "Amended Clinical Trial Protocol 11  \n20-Dec-2023 \nSAR442168-EFC16034 - tolebrutinib \nVersion number: 1 \nProperty of the Sanofi group - strictly confidential \nPage 12 \nObjectives \nEndpoints \n• \nTo eval"
    }
  }
}